New insider activity at Nuvation Bio ( (NUVB) ) has taken place on November 21, 2025.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Chief Technical Operations Officer Hanley David C. has recently sold 200,000 shares of Nuvation Bio stock, amounting to a total transaction value of $1,426,000.
Recent Updates on NUVB stock
Recent developments for Nuvation Bio (NUVB) have led to significant changes in analyst price targets, driven by promising clinical data and strategic advancements. Citizens JMP raised its price target due to the strong performance of safusidenib in a Phase 2 Japanese glioma study, which showed a significant overall response rate compared to a previous study. This success has encouraged Nuvation Bio to pursue further development in higher-grade glioma settings. Similarly, Wedbush increased its price target, maintaining an Outperform rating, reflecting confidence in the company’s strategic direction. B. Riley initiated coverage with a Buy rating, citing the positive commercial revenue ramp of the lead drug Ibtrozi in lung cancer, supported by its class-leading attributes. However, the company faces strategic challenges in commercializing taletrectinib globally, which could impact future profitability. Despite these risks, the overall outlook remains positive, with a strong buy consensus among analysts.
Spark’s Take on NUVB Stock
According to Spark, TipRanks’ AI Analyst, NUVB is a Neutral.
Nuvation Bio’s stock is primarily challenged by weak financial performance, characterized by ongoing losses and negative cash flows, despite a strong equity foundation. While there is short-term momentum in the stock price, the lack of sustainable income and negative valuation metrics, such as a negative P/E ratio, weigh heavily on the overall score. The stock’s speculative nature and reliance on future growth prospects contribute to its moderate overall score.
To see Spark’s full report on NUVB stock, click here.
More about Nuvation Bio
YTD Price Performance: 170.66%
Average Trading Volume: 8,717,006
Technical Sentiment Signal: Buy
Current Market Cap: $2.46B